Alphamab Oncology's novel cancer drug receives regulatory acceptance

Alphamab Oncology announced China's Center for Drug Evaluation accepted its Investigational New Drug application for JSKN022, a first-in-class bispecific antibody-drug conjugate targeting PD-L1 and integrin avβ6.

The company will initiate first-in-human clinical studies for advanced malignant solid tumors. Preclinical data demonstrated potent antitumor activity, offering potential treatment for resistant cancers.